Syncom FY26 Net Profit Rises 55.5% to ₹764.38 Crore
Syncom Formulations (India) Limited has submitted the press clipping for its audited standalone and consolidated financial results for the year ended March 31, 2026. The company reported a 55.5% increase in consolidated net profit to ₹764.38 crore for FY26, while Q4 net profit rose to ₹25.17 crore. Total income for the year grew to ₹5,205.11 crore, driven primarily by the Pharmaceuticals segment.
*this image is generated using AI for illustrative purposes only.
Syncom Formulations (India) Limited has submitted the press clipping related to the extract of its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company's board of directors had previously approved the financial statements during a meeting held on May 22, 2026. The statutory auditors issued an unmodified opinion on the results, confirming compliance with Indian Accounting Standards (Ind AS) and SEBI regulations. The advertisement regarding the results was published in the Business Standard journal on May 23, 2026.
Q4 Performance
Syncom Formulations' Q4 consolidated net profit rose to ₹25.17 crore from ₹17.69 crore in the corresponding quarter of the previous year, reflecting a year-on-year improvement in profitability. However, Q4 revenue came in at ₹135.41 crore, compared to ₹148.88 crore in the same period last year, indicating a decline on the top line for the quarter. The quarterly results highlight a divergence between profit growth and revenue performance during the period.
| Metric | Q4 FY26 | Q4 FY25 |
|---|---|---|
| Consolidated Net Profit | ₹25.17 Crore | ₹17.69 Crore |
| Revenue | ₹135.41 Crore | ₹148.88 Crore |
Consolidated Financial Performance
For the full financial year, the company reported a consolidated net profit of ₹764.38 crore, marking a 55.5% increase from the ₹494.35 crore recorded in the previous year. Total income for the period grew to ₹5,205.11 crore from ₹4,824.47 crore in FY25. Revenue from operations stood at ₹4,891.71 crore, while other income contributed ₹313.40 crore.
Standalone Results
On a standalone basis, the net profit for the year ended March 31, 2026, reached ₹760.08 crore, up from ₹488.72 crore in the corresponding period of the previous year. Total standalone income increased to ₹5,175.39 crore from ₹4,800.41 crore. Revenue from operations was reported at ₹4,865.73 crore. The company noted that it had restated its Earnings Per Share (EPS) calculations for prior periods to comply with Ind AS 33, using Profit After Tax instead of Total Comprehensive Income.
Segment Performance
The company operates across three primary segments: Pharmaceuticals Drugs & Formulations, Trading of Commodities, and Renting of Property. The Pharmaceuticals segment remained the primary revenue driver, contributing ₹5,157.34 crore to the total segment revenue for the year. The company also recognized an incremental cost of ₹87.81 lakh during the year related to the new Labour Codes notified by the Government of India.
Financial Position and Cash Flows
As of March 31, 2026, the company's consolidated total assets stood at ₹5,338.45 crore, compared to ₹4,132.81 crore in the previous year. Equity share capital remained constant at ₹940 crore. The net cash generated from operating activities for the year was ₹580.79 crore, while cash and cash equivalents at the end of the period totaled ₹51.48 crore. The following table summarizes the key full-year financial metrics:
| Metric | FY26 (₹ in Lacs) | FY25 (₹ in Lacs) | Change |
|---|---|---|---|
| Consolidated Net Profit | 76,438.00 | 49,434.60 | +55.5% |
| Consolidated Total Income | 5,20,511.40 | 4,82,446.60 | +7.9% |
| Standalone Net Profit | 76,008.00 | 48,871.80 | +55.5% |
| Standalone Total Income | 5,17,539.10 | 4,800,405.00 | +7.8% |
| Consolidated EPS (Basic) | 0.81 | 0.53 | +52.8% |
Historical Stock Returns for Syncom Formulations
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.56% | +3.84% | +5.05% | -9.64% | -28.34% | +77.04% |
What strategic initiatives is Syncom Formulations planning to address the Q4 revenue decline while sustaining its strong profit growth trajectory into FY27?
How might Syncom Formulations deploy its significantly expanded asset base of ₹5,338 crore to drive future revenue growth, given the relatively low cash and cash equivalents of ₹51.48 crore?
Will the company's Trading of Commodities and Renting of Property segments play a larger role in diversifying revenue streams as the Pharmaceuticals segment faces top-line pressure?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
